| Title: |
Eosinophils and eosinophil-associated disorders: immunological, clinical, and molecular complexity. |
| Authors: |
Valent, Peter; Degenfeld-Schonburg, Lina; Sadovnik, Irina; Horny, Hans-Peter; Arock, Michel; Simon, Hans-Uwe; Reiter, Andreas; Bochner, Bruce, S |
| Contributors: |
Medical University of Vienna = Medizinische Universität Wien (MedUni Vienna); Ludwig Maximilian University Munich = Ludwig Maximilians Universität München (LMU); CHU Pitié-Salpêtrière AP-HP; Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU); Sorbonne Université - Faculté de Médecine (SU FM); Sorbonne Université (SU); Universität Bern = University of Bern = Université de Berne (UNIBE); Sechenov First Moscow State Medical University; Kazan Federal University (KFU); Universität Heidelberg Heidelberg = Heidelberg University; Feinberg School of Medicine Northwestern University, Evanston ( Northwestern University Medical School ); Northwestern University Evanston |
| Source: |
ISSN: 1863-2297. |
| Publisher Information: |
CCSD; Springer Verlag |
| Publication Year: |
2021 |
| Subject Terms: |
Hypereosinophilia; Eosinophilic leukemia; FIP1L1-PDGFRA; Hypereosinophilic Syndromes; Classification; Targeted therapy; [SDV]Life Sciences [q-bio] |
| Description: |
International audience ; Eosinophils and their mediators play a crucial role in various reactive states such as bacterial and viral infections, chronic inflammatory disorders, and certain hematologic malignancies. Depending on the underlying pathology, molecular defect(s), and the cytokine- and mediator-cascades involved, peripheral blood and tissue hypereosinophilia (HE) may develop and may lead to organ dysfunction or even organ damage which usually leads to the diagnosis of a HE syndrome (HES). In some of these patients, the etiology and impact of HE remain unclear. These patients are diagnosed with idiopathic HE. In other patients, HES is diagnosed but the etiology remains unknown - these patients are classified as idiopathic HES. For patients with HES, early therapeutic application of agents reducing eosinophil counts is usually effective in avoiding irreversible organ damage. Therefore, it is important to systematically explore various diagnostic markers and to correctly identify the disease elicitors and etiology. Depending on the presence and type of underlying disease, HES are classified into primary (clonal) HES, reactive HES, and idiopathic HES. In most of these patients, effective therapies can be administered. The current article provides an overview of the pathogenesis of eosinophil-associated disorders, with special emphasis on the molecular, immunological, and clinical complexity of HE and HES. In addition, diagnostic criteria and the classification of eosinophil disorders are reviewed in light of new developments in the field. |
| Document Type: |
article in journal/newspaper |
| Language: |
English |
| Relation: |
info:eu-repo/semantics/altIdentifier/pmid/34052871; PUBMED: 34052871; PUBMEDCENTRAL: PMC8164832 |
| DOI: |
10.1007/s00281-021-00863-y |
| Availability: |
https://hal.sorbonne-universite.fr/hal-03251770; https://hal.sorbonne-universite.fr/hal-03251770v1/document; https://hal.sorbonne-universite.fr/hal-03251770v1/file/Valent2021_Article_EosinophilsAndEosinophil-assoc.pdf; https://doi.org/10.1007/s00281-021-00863-y |
| Rights: |
https://about.hal.science/hal-authorisation-v1/ ; info:eu-repo/semantics/OpenAccess |
| Accession Number: |
edsbas.7EA875BC |
| Database: |
BASE |